We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biota Fpo | ASX:BTA | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
From Jul 2019 to Jul 2024
GlaxoSmithKline PLC (GSK) Wednesday said it had begun a pivotal study testing intravenous zanamivir against Roche Holding AG's (ROG.VX) best-selling antiviral flu pill Tamiflu as a treatment for patients hospitalized with influenza.
The trial has a target enrolment of 462 patients planned in over 20 countries that take into account flu seasons in the northern and southern hemispheres. The study will take approximately three years, Glaxo said in a statement.
Intravenous zanamivir is not approved for sale in any country. An inhaled version of the medicine, originally developed by Australia's Biota Holdings LTD (BTA.AU) and licenced by Glaxo, has been available since 1999 under the brand name Relenza.
Sales of antivirals Relenza and Tamiflu soared in 2009 as countries stockpiled the drug to treat people infected with the H1N1 swine flu strain.
There is now evidence flu is again spreading across the U.K. and a number of European countries, with the main circulating forms being the H1N1 strain and Influenza B.
-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com
1 Year Biota Holdings Chart |
1 Month Biota Holdings Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
